Fig. 10

Assessment of tumor mutation burden (TMB) and drug responsiveness. A Waterfall plot illustrating the 20 most frequently mutated genes in breast cancer within a high-risk cohort consisting of 760 samples. B Waterfall plot illustrating the top 20 mutated genes in breast cancer for the low-risk cohort consisting of 779 samples. In A and B, the green bar indicated a missense mutation, the purple bar signified a frame shift insertion, the blue bar denoted a frame shift deletion, the yellow bar reflected an in-frame deletion, the orange bar pointed to a splice site, and the black bar represented a multi-hit event. C Comparison of TMB between high-risk and low-risk cohorts of breast cancer. D IC50 values for 5-Fluorouracil, Camptothecin, Doxorubicin, and Docetaxel in breast cancer high- and low-risk cohorts. In C and D, with the high-risk cohort denoted by red and the low-risk cohort by blue. E Relationship between model gene expression levels and drug sensitivity, based on predictions from the CellMiner database. EPB41L4B was negatively correlated with tepotinib (Cor = -0.498), NT5E was negatively correlated with AFP464 (Cor = -0.541). CD24 was positively correlated with Sapitinib (Cor = 0.473), SORBS1 positively correlated with PLX-4720 (Cor = 0.430)